Radiation Therapy With or Without Carbogen and Niacinamide in Treating Patients With Bladder Cancer

This study has been completed.
Sponsor:
Information provided by:
National Cancer Institute (NCI)
ClinicalTrials.gov Identifier:
NCT00033436
First received: April 9, 2002
Last updated: September 19, 2013
Last verified: December 2002

April 9, 2002
September 19, 2013
October 2000
Not Provided
  • Cystoscopic response at 6 months after initiation radiotherapy [ Designated as safety issue: No ]
  • Local failure-free survival [ Designated as safety issue: No ]
  • Overall disease-specific survival [ Designated as safety issue: No ]
Not Provided
Complete list of historical versions of study NCT00033436 on ClinicalTrials.gov Archive Site
  • Treatment related morbidity (i.e., acute and chronic bowel and bladder symptoms) [ Designated as safety issue: No ]
  • Quality of life as assessed by FACT-BI scale at baseline, week 4, 3 months, 6 months, 12 months, and yearly thereafter for 5 years [ Designated as safety issue: No ]
Not Provided
Not Provided
Not Provided
 
Radiation Therapy With or Without Carbogen and Niacinamide in Treating Patients With Bladder Cancer
A Multicenter Randomized Trial of Radical Radiotherapy With Carbogen in the Radical Treatment of Locally Advanced Bladder Cancer

RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Drugs such as carbogen and niacinamide may make tumor cells more sensitive to radiation therapy. It is not yet known whether radiation therapy is more effective with or without carbogen and niacinamide in treating patients who have bladder cancer.

PURPOSE: Randomized phase III trial to compare the effectiveness of radiation therapy with or without carbogen and niacinamide in treating patients who have locally advanced bladder cancer.

OBJECTIVES:

  • Compare the 6-month cystoscopic response in patients with locally advanced transitional cell carcinoma of the bladder treated with radical radiotherapy with or without radiosensitization with carbogen and niacinamide.
  • Compare the local failure-free and overall disease-specific survival of patients treated with these regimens.
  • Compare the treatment-related morbidity, in particular acute and chronic bowel and bladder symptoms, in patients treated with these regimens.
  • Compare the quality of life of patients treated with these regimens.

OUTLINE: This is a randomized, multicenter study. Patients are randomized to 1 of 2 treatment arms.

  • Arm I: Patients receive radical radiotherapy once daily, 5 days a week, for 4-6.4 weeks. Patients also receive oral niacinamide once daily 1.5-2 hours before initiation of each radiotherapy dose and carbogen through a closed breathing system (face mask with a tight air seal or a mouthpiece with nasal clip) once daily beginning 5 minutes before initiation and continuing until completion of each radiotherapy dose.
  • Arm II: Patients receive radiotherapy as in arm I. Quality of life is assessed at baseline; at 4 weeks; at 3, 6, and 12 months; and then annually for 4 years.

Patients are followed at 8 and 12 weeks; at 6, 9, and 12 months; and then every 6 months for 4 years.

Peer Reviewed and Funded or Endorsed by Cancer Research UK

PROJECTED ACCRUAL: A total of 330 patients (165 per treatment arm) will be accrued for this study.

Interventional
Phase 3
Allocation: Randomized
Primary Purpose: Treatment
Bladder Cancer
  • Dietary Supplement: niacinamide
  • Drug: carbogen
  • Radiation: radiation therapy
Not Provided
Hoskin PJ, Rojas AM, Saunders MI, Bentzen SM, Motohashi KJ; BCON investigators. Carbogen and nicotinamide in locally advanced bladder cancer: early results of a phase-III randomized trial. Radiother Oncol. 2009 Apr;91(1):120-5. Epub 2008 Nov 5.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
330
November 2008
Not Provided

DISEASE CHARACTERISTICS:

  • Histologically confirmed transitional cell carcinoma of the bladder

    • Muscle invasive carcinoma (stage T2 or T3) of any grade OR
    • High-grade (G3) superficial bladder carcinoma (T1) OR
    • Prostatic invasion (T4a)
  • No squamous cell carcinoma or adenocarcinoma of the bladder
  • No locally advanced T4b carcinoma
  • No distant metastasis or enlarged pelvic lymph nodes on CT staging scan of the pelvis

PATIENT CHARACTERISTICS:

Age:

  • Over 18

Performance status:

  • Not specified

Life expectancy:

  • Not specified

Hematopoietic:

  • Not specified

Hepatic:

  • Bilirubin no greater than 2 times normal

Renal:

  • Creatinine no greater than 2 times normal

Cardiovascular:

  • No ischemic heart disease or peripheral vascular disease requiring diuretics or angiotensin-converting enzyme inhibitors

Pulmonary:

  • No concurrent respiratory disease with reduced respiratory drive that would preclude the delivery of 95% oxygen

Other:

  • Capable of complying with a closed breathing system delivering carbogen through either a mask or a mouthpiece with nasal clip

PRIOR CONCURRENT THERAPY:

Biologic therapy:

  • Not specified

Chemotherapy:

  • Not specified

Endocrine therapy:

  • Not specified

Radiotherapy:

  • Not specified

Surgery:

  • Not specified
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United Kingdom
 
NCT00033436
CDR0000069283, MTVERNHOSP-BCON, EU-20051
Not Provided
Not Provided
Mount Vernon Cancer Centre at Mount Vernon Hospital
Not Provided
Study Chair: Peter J. Hoskin, MD Mount Vernon Cancer Centre at Mount Vernon Hospital
National Cancer Institute (NCI)
December 2002

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP